Kiss frontman Gene Simmons has stepped down from his role as chief evangelist officer at Invictus MD Strategies Corp (TSXV: GENE).
The group’s shares traded under the ticker IMH until Simmons joined the company in March 2018. He was brought in to help Invictus with its marketing strategy and branding efforts in anticipation of recreational cannabis being legalized in Canada.
At the time, Invictus founder Dan Kriznic called him “a branding and merchandising genius”, hailing his success within diverse product categories including T-shirts comic books, pinball machines, credit cards and lunchboxes, while breaking box office records set by The Beatles and Elvis.
Since then he has served as the Vancouver-based firm’s media spokesman and he has made appearances at promotional events, investor briefings and board meetings.
Yet Simmons has now decided to abdicate the role, although he will remain a shareholder in the business. “I have enjoyed my time with Invictus,” he said. “I remain a big fan.”
Invictus went public in 2014 and it grew through early acquisitions. Kriznic announced his resignation as chairman and chief executive with immediate effect on Nov. 5, 2018.
Paul Sparkes took over as chairman and George E. Kveton was installed as chairman in what the company described as a “go forward leadership team”. Both men had served on the board for several years.
Trevor Dixon then stepped down as president and director in January 2019, although he stayed on as president of wholly-owned subsidiary Acreage Pharms Ltd, the firm he founded. Within two months, Dixon was named chief operating officer at Invictus and he was back on the board once more.
On May 31, Kveton resigned and Dixon assumed the CEO role. Simmons remained in place throughout all these changes, but he has now left too, so it is time for Invictus to begin a new chapter, but it did not comment on whether it would retain the GENE ticker.
Invictus’ share price was $0.87 at the beginning of 2019 and it has decreased to $0.34 since then.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.